



Chronic Malignancies Working Party Educational Meeting

Warsaw, Poland
22-23 November 2024

Welcome!

The Chronic Malignancies Working Party (CMWP) of EBMT is delighted to announce our Scientific Business Meeting and Educational Meeting which will be held on 22 and 23 November 2024 in Warsaw, Poland. The specific focus of this meeting will be on optimisation of allogeneic HCT for MDS, MPN and MDS/MPN overlap syndromes.

The Scientific Business Meeting gives an opportunity to hear about the progress of our study portfolio, suggest new studies and contribute to the work of the CMWP.

The Educational Meeting on Saturday 23rd November will consist of a comprehensive series of presentations from local and international experts with ample time for questions and debate on challenging scenarios we all face in our practice!

Topics will include "MDS classification in 2024 – ICC versus WHO and the allo-HCT decision", "Germline predisposition traits: considerations in allo-HCT for MDS", "Transplant for TP53 mutated MDS: how to approach in 2024", "Optimisation of Haploidentical allo-HCT for Myelofibrosis", "Novel GVHD strategies for allo-HCT in Myelofibrosis", "How to manage cases of MDS/MPN- unclassifiable" and "Improving outcomes for allo-HCT for CMML", amongst many other topics including case presentations.

The audience will gather together local, national and international transplantation experts from the nursing, medical and clinical data management and biostatistics expert community.

We very much look forward to meeting you in Warsaw and discussing these exciting topics in the field of allo-HCT and MDS, MPN and MDS/MPN!

Donal McLornan — *Chronic Malignancies Working Party Chair*

Kavita Raj — *Chronic Malignancies Working Co-Secretary*

Joanna Drozd-Sokolowska — *Chronic Malignancies Working Co-Secretary & Local Organiser*

Friday, 22 November 2024

10:00 – 16:30 Chronic Malignancies Working Party Scientific Business Meeting

Saturday, 23 November 2024

08:30 – 08:45	Welcome and overview of the Working Party <i>Chairs: Joanna Drozd-Sokołowska (PL), Donal McLornan (UK) & Kavita Raj (UK)</i>	
08:45 – 10:25	Session I: Allo-HCT for MDS in 2024 <i>Chairs: Joanna Drozd-Sokołowska (PL) & Kavita Raj (UK)</i>	
08:45 – 09:00	MDS classification in 2024: ICC versus WHO and the allo-HCT decision	Joanna Drozd-Sokołowska (PL)
09:00 – 09:15	The IPSS-Molecular: Using IPSS-M to guide allo-HCT decisions for MDS	Grzegorz Basak (PL)
09:15 – 09:20	Discussion + Q&A	
09:20 – 09:35	Germline predisposition traits: considerations in allo-HCT for MDS	Carmelo Gurnari (IT)
09:35 – 09:50	Transplant for <i>TP53</i> mutated MDS: how to approach in 2024	Kavita Raj (UK)
09:50 – 09:55	Discussion + Q&A	
09:55 – 10:10	Integrating Novel drugs into the MDS allo-HCT algorithm	Krzysztof Mądry (PL)
10:10 – 10:20	<i>Case Presentation: Managing TP53-Mutant MDS: A Case of Successful Allogeneic Transplantation and Post-Transplant Salvage Therapy</i>	Angela Consagra (IT)
10:20 – 10:25	Discussion + Q&A	
10:25 – 11:00	Coffee Break	
11:00 – 13:00	Session II: Improving Allo-HCT Outcomes for MPN <i>Chairs: Juan Carlos Hernandez Boluda (SP) & Donal McLornan (UK)</i>	
11:00 – 11:15	Optimization of GVHD prophylaxis strategies in MF allo-HCT	Juan Carlos Boluda (SP)
11:15 – 11:30	Role of $\alpha\beta$ T cell depletion in allo-HCT for MF	Moniek de Witte (NL)
11:30 – 11:35	Discussion + Q&A	
11:35 – 11:50	Haploidentical Transplantation for MF	Tomasz Czerw (PL)
11:50 – 12:05	Management of poor graft function and relapse in MF allo-HCT	Giorgia Battipaglia (IT)
12:05 – 12:10	Discussion + Q&A	
12:10 – 12:25	Allo-HCT for atypical MPN: EBMT position	Nicola Polverelli (IT)
12:25 – 12:50	How best to approach Donor Lymphocyte Infusions in MF allo-HCT: 1. Case-based illustrative cases 2. A novel CAR-T cell therapy for Calreticulin mutated myelofibrosis	Nico Gagelmann (DE) Alex Rampotas (UK)
12:50 – 13:00	Discussion + Q&A	
13:00 – 13:45	Lunch Break	
13:45 – 14:20	Session III: Improving Patient and Caregiver Satisfaction Treatment Decisions for MDS and MPN <i>Chairs: Fernando Duarte (BR) & Maaïke de Ruijter (NL)</i>	
13:45 – 14:00	Can we incorporate patient preferences in clinical trial design for novel agents in MDS and MPN?	Esra Gülderen (TR)
14:00 – 14:15	Can we decrease the psychological burden for patients with MDS in the allogeneic HCT decision process? - self administration with Azacitidine	Sara Petterson (SE)
14:15 – 14:20	Discussion + Q&A	
14:20 – 15:45	Session IV: Optimizing Outcomes for MDS/MPN overlap syndromes <i>Chairs: Katja Sockel (DE) & Francesco Onida (IT)</i>	
14:20 – 14:35	How to manage cases of MDS/MPN- unclassifiable/NOS	Donal McLornan (UK)
14:35 – 14:50	Role of Novel agents in the management of CMML: an update	Katja Sockel (DE)
14:50 – 15:05	Improving outcomes for allo-HCT in CMML: the Brazilian experience	Fernando Duarte (BR)
15:05 – 15:25	Improving outcomes for allo-HCT in CMML: the EBMT position	Francesco Onida (IT)
15:25 – 15:35	<i>Case Presentation: Haploidentical donor stem cell transplant with posttransplant cyclophosphamide as initial therapy in a patient with Myelofibrosis</i>	Gonzalo Bentolila (AR)
15:35 – 15:40	Discussion + Q&A	
15:40 – 15:45	Closing remarks	Joanna Drozd-Sokołowska (PL)



Chronic Malignancies Working Party Educational Meeting

Warsaw, Poland
22-23 November 2024

SPECIAL THANKS TO OUR SPONSORS

BRONZE PARTNERS

The Abbvie logo is the word "abbvie" in a lowercase, dark blue, rounded sans-serif font.

abbvie

The Bristol Myers Squibb logo consists of a stylized icon of three vertical bars of increasing height to the left of the company name "Bristol Myers Squibb" in a dark grey, sans-serif font, followed by a registered trademark symbol.

 Bristol Myers Squibb®